Nasdaq First North

Inna Braverman, CEO of Eco Wave Power, Conducts Site Visit at Port Adriano in Mallorca to Promote its First Wave Energy Project in Spain

Retrieved on: 
Monday, May 16, 2022 - 2:18pm

Upon completion of such steps, Eco Wave Power will move forward to the detailed project planning phase to be followed by actual construction.

Key Points: 
  • Upon completion of such steps, Eco Wave Power will move forward to the detailed project planning phase to be followed by actual construction.
  • Eco Wave Power's floaters will directly connect to the 500-meter breakwater at Port Adriano and to the nearby substations of the port.
  • We are also very pleased to do so specifically in Port Adriano, which is a pioneering and innovative port in Spain.
  • "We're proud to be the future home of the first Eco Wave Power project in Spain."

Inna Braverman, CEO of Eco Wave Power, Conducts Site Visit at Port Adriano in Mallorca to Promote its First Wave Energy Project in Spain

Retrieved on: 
Monday, May 16, 2022 - 2:16pm

Upon completion of such steps, Eco Wave Power will move forward to the detailed project planning phase to be followed by actual construction.

Key Points: 
  • Upon completion of such steps, Eco Wave Power will move forward to the detailed project planning phase to be followed by actual construction.
  • Eco Wave Power's floaters will directly connect to the 500-meter breakwater at Port Adriano and to the nearby substations of the port.
  • We are also very pleased to do so specifically in Port Adriano, which is a pioneering and innovative port in Spain.
  • "We're proud to be the future home of the first Eco Wave Power project in Spain."

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Retrieved on: 
Monday, May 16, 2022 - 7:25am

TURKU, Finland and BOSTON, May 16, 2022 /PRNewswire/ -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that both the U.S. Food and Drug Administration (FDA) and Finnish Medicines Agency (FIMEA) have cleared Faron's Investigational New Drug (IND) application to begin the Company sponsored BEXMAB study. BEXMAB is a novel Phase I/II study to assess safety, tolerability and preliminary efficacy of bexmarilimab, Faron's wholly-owned investigational precision cancer immunotherapy, in combination with standard of care (SoC) therapy in patients with relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CML). This marks the first time bexmarilimab will be assessed as part of a clinical study in hematologic malignancies.

Key Points: 
  • In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes.
  • As an immuno-oncology therapy, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules.
  • Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system.
  • Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

DGAP-News: Eleving Group S.A.: Eleving Group (former Mogo Finance) reports unaudited results for the three months ended 31 March 2022

Retrieved on: 
Friday, May 13, 2022 - 7:04pm

Vehicle and Consumer Financing Portfolio has reached EUR 259.9 mlna record-high for the company and a 41.6% increase compared to Q1 2021.

Key Points: 
  • Vehicle and Consumer Financing Portfolio has reached EUR 259.9 mlna record-high for the company and a 41.6% increase compared to Q1 2021.
  • Modestas Sudnius, CEO of Eleving Group, commented: In the first quarter of 2022, Eleving Group has been successful both operationally and financially.
  • During the first quarter of 2022, we continued to demonstrate strong results across our markets and business lines.
  • The full unaudited report for the three months ended 31 March 2022 is available under: https://eleving.com/investors/
    A conference call in English with the Group's management team to discuss the results is scheduled for 17 May2022 at 15:00 CET.

Eco Wave Power to Begin Providing Information in English Only

Retrieved on: 
Tuesday, May 10, 2022 - 2:25pm

Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves.

Key Points: 
  • Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves.
  • Eco Wave Power is recognized as a "Pioneering Technology" by the Israeli Ministry of Energy and was labeled as an "Efficient Solution" by the Solar Impulse Foundation.
  • Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program.
  • Eco Wave Power's common shares (ECOWVE) are traded on Nasdaq First North and its ADSs (WAVE) are traded on the Nasdaq Capital Market.

Eco Wave Power to Begin Providing Information in English Only

Retrieved on: 
Tuesday, May 10, 2022 - 2:24pm

Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves.

Key Points: 
  • Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves.
  • Eco Wave Power is recognized as a "Pioneering Technology" by the Israeli Ministry of Energy and was labeled as an "Efficient Solution" by the Solar Impulse Foundation.
  • Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program.
  • Eco Wave Power's common shares (ECOWVE) are traded on Nasdaq First North and its ADSs (WAVE) are traded on the Nasdaq Capital Market.

Eco Wave Power Files Annual Report on Form 20-F for the Year Ended December 31, 2021

Retrieved on: 
Thursday, April 28, 2022 - 11:21pm

The annual report, which contains Eco Wave Power's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov as well as via the Company's website at SEC Filings .

Key Points: 
  • The annual report, which contains Eco Wave Power's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov as well as via the Company's website at SEC Filings .
  • Eco Wave Power is a leading onshore wave energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity.
  • Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program.
  • Eco Wave Power's common shares (ECOWVE) are traded on Nasdaq First North and its ADSs (WAVE) are traded on the Nasdaq Capital Market.

Eco Wave Power Files Annual Report on Form 20-F for the Year Ended December 31, 2021

Retrieved on: 
Thursday, April 28, 2022 - 11:09pm

The annual report, which contains Eco Wave Power's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov as well as via the Company's website at SEC Filings .

Key Points: 
  • The annual report, which contains Eco Wave Power's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov as well as via the Company's website at SEC Filings .
  • Eco Wave Power is a leading onshore wave energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity.
  • Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program.
  • Eco Wave Power's common shares (ECOWVE) are traded on Nasdaq First North and its ADSs (WAVE) are traded on the Nasdaq Capital Market.

Leading Edge Materials Announces Results Of Annual and Special Meeting of Shareholders

Retrieved on: 
Thursday, April 28, 2022 - 10:00pm

Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union.

Key Points: 
  • Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union.
  • Critical raw materials are determined as such by the European Union based on their economic importance and supply risk.
  • Leading Edge Materials is listed on the TSXV under the symbol LEM, OTCQB under the symbol LEMIF and Nasdaq First North Stockholm under the symbol "LEMSE".
  • The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

Retrieved on: 
Thursday, April 7, 2022 - 6:00am

Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter Onxeo or the Company, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the appointment of Dr. Shefali Agarwal as President and Chief Executive Officer.

Key Points: 
  • Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter Onxeo or the Company, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the appointment of Dr. Shefali Agarwal as President and Chief Executive Officer.
  • She will remain an advisor to Epizyme in a consultant role while fulfilling her duties at Onxeo.
  • Given my deep experience in oncology, Im encouraged by the work weve done at Onxeo and by the opportunities our platON platform has generated, said Dr. Shefali Agarwal.
  • Robert L. Coleman, MD, Onxeo Board member and Chief Scientific Officer of US Oncology Research, said, We are excited to welcome Dr. Agarwal to Onxeo as CEO.